MAKE APPOINTMENT

Insurers Rejected 84% of Commercial and 65% of Medicare Claims for Oral Blood Cancer Drugs at First Submission

by | Oct 2, 2026 | Uncategorized | 0 comments

A peer-reviewed study found insurers first rejected 84% of commercial and 65% of Medicare claims for oral blood cancer drugs in 2022.

Submit a Comment

Your email address will not be published. Required fields are marked *